The Thread Formerly Known as No Rest For The Wicked Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JeffA who wrote (33769)	4/28/1999 3:39:00 PM
From: MARK C.	Read Replies (1) of 90042

357, I know PFE is only the marketer of Celebrex and as far as I know labeling has not yet been decided on Vioxx. I was only saying that PFE is over sold and will run into the split. PFE also comarkets Lipitor for Warner Lambert. PFE has been heavily investing in Gene sequencing companies. PFE's successful partnering strategy will only bring more of the same to them as young startup drug companies look for a way to get their wares marketed on a scale they can hardly afford. MTC is a company in the process of turning things around and I think in the long run their best bet is going to be in the strong agri-bio business they are building. JMHO, MarkC.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next